1158548-82-3

Basic information

• Product Name: 4-(PIPERAZINOMETHYL)BENZONITRILE, HYDROCHLORIDE
• Synonyms: 4-(PIPERAZINOMETHYL)BENZONITRILE, HYDROCHLORIDE
• CAS NO: 1158548-82-3
• Molecular Formula: C12H16ClN3
• Molecular Weight: 237.72854
• Product Categories: Aromatics Compounds;Aromatics
• Mol File: 1158548-82-3.mol
• Article Data: 1

Chemical Properties

• Melting Point: 285-308°C dec.
• Appearance: /
• Solubility: Water
• CAS DataBase Reference: 4-(PIPERAZINOMETHYL)BENZONITRILE, HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PIPERAZINOMETHYL)BENZONITRILE, HYDROCHLORIDE(1158548-82-3)
• EPA Substance Registry System: 4-(PIPERAZINOMETHYL)BENZONITRILE, HYDROCHLORIDE(1158548-82-3)

Safety Data

• Hazardous Substances Data: 1158548-82-3(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

4-(Piperazinomethyl)benzonitrile, Hydrochloride (cas# 1158548-82-3) is a compound useful in organic synthesis.

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 849237-14-5 4-(4-cyanobenzyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Novel indirect AMP-activated protein kinase activators: Identification of a second-generation clinical candidate with improved physicochemical properties and reduced hERG inhibitory activity

This study reports the synthesis and evaluation of novel indirect AMP-activated protein kinase (AMPK) activators. The series of compounds selectively inhibited cell growth in several human breast cancer cell lines by activating AMPK. We performed back-up medicinal chemistry synthetic research on ASP4132, a previously reported as a compound for clinical development that acts as an indirect AMPK activator. This led to the successful identification of 4-({4-[5-({1-[(5-ethoxypyrazin-2-yl)methyl]-4-fluoropiperidin-4-yl}methoxy)-3-methylpyridine-2-carbonyl]piperazin-1-yl}methyl)benzonitrile succinate (27b), a potent, highly aqueous soluble and metabolically stable compound in human hepatocytes. Compound 27b also showed weaker human Ether-a-go-go Related Gene (hERG) inhibitory activity than that of compound 13 and ASP4132. Therefore, 27b was a promising AMPK activator and a second-generation clinical candidate for treatment for human cancer.